RAPP SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Nov 4, 2026

8-K

Rapport Therapeutics Announces Closing of Common Stock and Convertible Senior Notes Offerings Raising Over $382 Million

Oct 30, 2026

8-K

Phase 2 Trial Shows RAP-219 Significantly Improves Bipolar Mania Symptoms and Is Well Tolerated, Supporting Planned Phase 3 Development

Oct 20, 2026

8-K

Rapport Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Progress

Aug 5, 2026

8-K

Rapport Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 10, 2026

8-K

Rapport Therapeutics Reports First Quarter 2026 Financials and Business Update

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Oct 30, 2026

424B5

REGISTERED OFFERING

Oct 30, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Morgan Stanley

Oct 27, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Morgan Stanley

Oct 27, 2026

424B5

January 2026 ATM | Offering amount: $110,000,000

Jan 7, 2026

424B5

SHELF OFFERING | Shares amount: 9,615,385 | Share price: $26 | Offering amount: $250,000,010 | Bank: Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel

Sep 10, 2025

Registrations

TYPE

HEADLINE

FILED AT

FWP

OFFERING

Oct 28, 2026

FWP

OFFERING

Oct 28, 2026

FWP

OFFERING

Oct 27, 2026

FWP

OFFERING

Oct 27, 2026

S-3ASR

March 2026 SHELF + ATM

Mar 10, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 10, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Third Rock Ventures V, L.P. (Reporting)

Nov 3, 2026

HEALY JAMES (Reporting)

Oct 30, 2026

Ceesay Abraham (Reporting)

Oct 23, 2026

Sanchez Ramiro (Reporting)

Oct 23, 2026

Silva Paul M (Reporting)

Oct 22, 2026

Young Wendy B. (Reporting)

Oct 22, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 10, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 10, 2025

CORRESP

Form CORRESP - Correspondence

Jul 7, 2025

CORRESP

Form CORRESP - Correspondence

Jul 7, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 7, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 7, 2025

Rapport Therapeutics, Inc. Common Stock RAPP · SEC Filings